

PubMed

Abstract

Full text links

BMC Med. 2015 May 9;13:109. doi: 10.1186/s12916-015-0344-1.



The need for a personalized approach for prostate cancer management.

Sedelaar JP¹, Schalken JA².

Author information

¹Radboud University Medical Center, Nijmegen, The Netherlands. Michiel.sedelaar@radboudumc.nl.

²Radboud University Medical Center, Nijmegen, The Netherlands. Jack.schalken@radboudumc.nl.

Abstract

The stratification of patients for treatment of prostate cancer is based on very general parameters like prostate-specific antigen, Gleason score, and TNM classification. We use these rough parameters for selection of active surveillance, active treatment, and even for the treatment selection in metastasized or castration-resistant prostate cancers. Up to now, we have not used individualized genetic classifiers for detailed sub-stratification, thus treating all patients as equal, and being only moderately successful. With the expected increase in systemic treatments, there is an apparent need for such classifiers. We will address these needs in this short commentary.


Comment on

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. [J Clin Oncol. 2015]

PMID: 25956920 [PubMed - indexed for MEDLINE] PMCID: PMC4425856 [Free PMC Article](#)



Images from this publication. [See all images \(1\)](#) [Free text](#)



Publication Types, MeSH Terms

LinkOut - more resources

[PubMed Commons](#)

[PubMed Commons home](#)